Norwegian version of this page

Diseases of esophagus and stomach

The group consists of surgeons, oncologists and pathologists and works for optimization of treatment.

About the group

Purpose of the group is

  • To evaluate by quality assurance existing surgical treatment of diseases of esophagus and stomach, as well as hernia, in order to improve treatment (e.g. robotic assisted surgery/new mesh techniques)
  • To participate in research studies within this field, both clinically and by molecularly in order to improve treatment (e.g. biomarkers for early detection of cancer/type of neoadjuvant/perioperative treatment/type of definitive oncologic treatment) 

The group has several focus areas and works mainly with

  • Oncological and surgical treatment of patients with esophageal and gastric ventricular cancer focusing on complications and survival.
  • Surical treatment of patients with benign diseases in the esophagus such as perforations, achalasia and diverticles.
  • Treatment of postoperative ventral and ingunial hernia (scarring).

The group participates in international studies on oncological and surgical treatment of esophageal and gastric cancer.

Evaluation of results by benign diseases is also an important tool for understanding and optimizing cancer treatment. In addition, the group assesses participation in studies that coincide with treatment programs.

Projects and Research

  • NeoRes II, Scandinavian multicenter randomized study  evaluating effect of awaiting surgery after chemoradiotherapy (CROSS regimen) for 4-6 versus 10-12 weeks is terminated and results planned for publication. 
  • Continual monitoring of complications and survival (quality assurance) following resection for esophageal- and gastric cancer
  • Continuous biobanking of blood samples and tumor tissue ((esophageal cancer (n= 380), gastric cancer (n=260)) to a biobank since 2013 for research purposes.  Analyses of biobank material have been ongoing since 2019.
  • Manuscript on results (survival/compications) from hybrid resection of esophageal cancer is accepted in Acta Oncol (PhD study).
  • Studies on esophageal cancer on biomarkers /local treatment of dysplasia and early cancer/total minimally invasive resection for more advanced cancer are ongoing (PhD study)
  • A pilot project on to studying microcirculatory changes in the gastric tube before, under and after surgery for esophageal cancer has been completed. Results are planned for publication.
  • The INNOVATION study. European randomised multicenter study, in which patients with HER-2 positive gastric cancer were randomized in three arms for i) chemotherapy, ii) chemotherapy with trastuzumab or iii) chemotherapy with trastuzumab+pertuzumab. End point is overall survival.  EORTC study. Inclusion is still ongoing. 
  • INTENSE study.  Effect of perioperative use of chemotherapy (FOLFIXFLIRI) in patients with resectable gastric and gastroesophageal junction adenocarcinoma.  Ongoing inclusion.
  • NEEDS study. Neoadjuvant chemoradiotherapy for esophageal  squamous cell carcinoma versus definitive chemoradiotherapy with salvage surgery as deeded. Under planning.
  • Keynote 061 (randomised study with palliative chemmotherapi in 2. line for gastric cancer; standard chemotherapy vs.  MK3475. MSD study. Inclusion from August 2015.
  • Keynote 180 (phase II study, palliative chemotherapy in 3. line for esophageal cancer; MK3474). MSD study. Inclusion from January 2016. 
  • Keynote 181 (randomised phase III study, palliative chemoterapy in 2. line for esophageal cancer;  standard chemotherapy vs MK3475). MSD study. Inclusion from January 2016.
  • Nordic NEC registry (registry study for all patients with neuroendocrine carcinoma of the GI-tract (GEP-NEC)). Inclusion from 2013. NNTG (Nordic Neuroendocrine Tumor Group). See reference 3 in the publication list (GO Hjortland is co-author).
  • ET-NEC. Nordic one armed phase II study for patients with GEP-NEC, Ki67 index 20-55%, first line treatment with everolimus and temozolomid. Inclusion from October 2014. NNTG study.

Cooperation

Internal

  • Truls Hauge and colleagues at Gastromedical Dep.,OUS,Ullevål
  • Geir Olav Hjortland and colleagues at the Oncological department,OUS,Ullevål
  • Guro Elisabeth Lind and colleagues at Dep. of Molecular Oncology, Institute of Cancer Reseach, OUS,DNR  

International

  • Magnus Nilsson and colleagues at the Gastrosurgical dep., Karolinska University Hospital, Sweden
  • Yvette M. Claassen and C.J.H. van de Velde in EURECCA (European Registration of Cancer Care), Datacenter Heelkunde, K6-R,  Leiden University Medical Center, Netherlands, in two international projects (see below)

Selected Publications

  • Amdal CD, Jacobsen AB, Falk RS, Johnson E, OS SS, Warloe T, Bjordal K. Improved        treatment decisions in patients with esophageal cancer. Acta Oncol 2017;56(10):1286-1294.
  • Galleberg RB, Knigge U, Tiensu JE, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H,  Österlund P, Hjortland GO, Assmus J, Tang L, Perren A. Sorbye H. Results after surgical treatment in  patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol  2017; 43 (9):1682-89.
  • Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer S,      Welin S, Vestermark LW, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET. “Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma (WHO G3)”. PLoS  One 12(11):e0187667, Nov7 2017.
  • Li Y, Li X, Kan Q, Zhang M, Li X, Xu R, Wang J, Goscinski MA, Wen JG, Nesland JM, Suo Z.     mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. Oncotarget 2017;8(1):1058-73.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after stenting and débridement for spontaneous esophageal rupture. Scand J Gastroenterol 2018;53(4):398-402.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome food bolus induced   esophageal perforation.  Scand J Gastroenterol 2018;53(8):905-909.
  • Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: EURECCA upper gastrointestinal group analysis. Eur J Surg Oncol. 2018;44(12):1982-1989.
  • Mala T, Johannessen HO, Førland D, Jacobsen TH, Johnson E. Laparoscopic resection for gastric cancer at Oslo University Hospital, Ullevål 2015-18. Tidsskr Nor Laegeforen. 2018; 138 (18). Doi:10.4045/tidsskr. 18.0404.
  • Claassen YHM, Bastiannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Shutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Koessler T, Chevallay M, Allum WH, vand de Velde CJH. International comparison of treatment strategy and survival in metastatic gastric cancer. BJS Open. 2019;3:56-61.
  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after iatrogenic   esophageal perforation. Scand J Gastroenterol. 2019 Feb;54(2):140-144.

 

Published Aug. 10, 2018 10:33 AM - Last modified Apr. 29, 2020 9:57 AM

Contact

Group Leader

Participants

  • Egil Johnson
  • Else Marit Løberg
  • Al-Haidari Ghazwan
  • Brit Dybdahl
  • Caroloine Ursin skagemo
  • Dag T. Førland
  • Geir Olav Hjortland
  • Hans-Olaf Johannessen
  • Jorunn Skattum
  • Tobias Hauge
  • Torgeir Thorson Søvik
Detailed list of participants